PepsiCo earnings beat estimates, but demand for drinks and snacks drops in North America

PepsiCo earnings beat estimates, but demand for drinks and snacks drops in North America


Bottles of Pepsi soda are seen on display at a Target store on February 09, 2024 in the Flatbush neighborhood of Brooklyn borough New York City.

Michael M. Santiago | Getty Images

PepsiCo reported mixed quarterly results on Tuesday as demand for its snacks and drinks fell in North America for the fifth straight quarter.

Shares of the company fell more than 1% in premarket trading.

Here’s what the company reported compared with what Wall Street was expecting, based on a survey of analysts by LSEG:

  • Earnings per share: $1.96 adjusted vs. $1.94 expected
  • Revenue: $27.78 billion vs. $27.89 billion expected

Pepsi reported fourth-quarter net income attributable to the company of $1.52 billion, or $1.11 per share, up from $1.3 billion, or 94 cents per share, a year earlier.

Excluding restructuring, impairment charges and other items, the food and beverage company earned $1.96 per share.

Net sales dropped 0.2% to $27.78 billion.

The company’s organic revenue, which excludes acquisitions, divestitures and foreign exchange, rose 2.1% in the fourth quarter.

Pepsi’s worldwide volume increased 1% for convenient foods and 1% for beverages. The metric strips out pricing and foreign exchange.

But demand was weaker in the company’s home market, North America. Pepsi has previously said that shoppers in the U.S. have grown more cautious, snacking less and making fewer purchases at convenience stores.

Frito-Lay North America’s volume fell 3% in the quarter. Consumers have been snacking less as they watch their grocery budgets, thanks to several years of higher food prices and interest rates.

“In 2024, the salty and savory snack categories underperformed broader packaged food, following multiple years in which these categories had outperformed packaged food,” CEO Ramon Laguarta and CFO Jamie Caulfield said in prepared remarks.

The company’s North American beverage unit reported a 3% decline in quarterly volume. But there were some bright spots for the division, as Gatorade gained market share and Mountain Dew Baja Blast surpassed $1 billion in annual sales.

Quaker Foods North America, still reeling from a recall from the prior December, saw its volume fall 6%. The company expects that Quaker’s performance will improve in 2025 as it laps the fallout from the recall, executives said in prepared remarks.

For 2025, Pepsi is projecting a low-single digit increase in its organic revenue and a mid-single digit increase in its core constant currency earnings per share.

“Looking ahead to 2025, we will continue to build upon the successful expansion of our international business, while also taking actions to improve performance in North America,” Laguarta said in a statement.



Source

Inside the booming business of wellness third spaces and membership clubs
Business

Inside the booming business of wellness third spaces and membership clubs

A few years ago, Grace Guo began to crave places in New York City where hanging out with friends didn’t have to involve alcohol. Newly sober and surrounded by friends who also chose not to drink, Guo said she wanted alternatives to the typical social scene. After some research, she landed on Bathhouse and Othership: […]

Read More
FDA vaccine head will step down in April after string of controversial decisions
Business

FDA vaccine head will step down in April after string of controversial decisions

The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the […]

Read More
FDA reversals leave investors worrying about the fates of other experimental drugs
Business

FDA reversals leave investors worrying about the fates of other experimental drugs

Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration.  The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from […]

Read More